Anne Debourgogne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anne Debourgogne has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Lyse Babin
UR 7300 SIMPA, Stress Immunity Pathogens Laboratory, Faculty of Medicine, Lorraine University, 9 Avenue de la Forêt de Haye, F-54500 Vandœuvre-lès-Nancy, France
2 shared publications Claire Cottrel
Université de Lorraine, SIMPA, F-54000 Nancy, France; Université de Lorraine, CHRU-Nancy, Laboratoire de Microbiologie, F-54000 Nancy, France
2 shared publications- Jean-Pol Frippiat
UR SIMPA, Stress Immunity Pathogens Laboratory, Faculty of Medicine, Lorraine University, Vandœuvre-lès-Nancy, France
2 shared publications A Berceanu
Hematology Department, Besançon Hospital , Besançon
1 shared publication- A Charmillon
Infectious Diseases Department in Charge of Mobile Infectiology Team, CHRU de Nancy-Brabois , Vandoeuvre-lès-Nancy
1 shared publication Agnes Melone
CHRU-Nancy, Biopathologie, Université de Lorraine , Nancy
1 shared publication
Latest Publications
- 31 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Typage moléculaire du complexe d'espèces Fusarium solani et détermination de son mécanisme de résistance au voriconazole
Le complexe d'espèces Fusarium solani regroupe des champignons phytopathogènes également impliqués en pathologie humaine dans des infections parfois profondes et souvent de mauvais pronostic. Dans un premier temps, une méthode de MLST, s'appuyant sur 5 gènes de ménage a donc été développée. Validée sur 51 isolats épidémiologiquement distincts, cette méthode stable et reproductible présente un pouvoir discriminant de 99,1 %. Après comparaison à la technique de référence utilisée en phylogénie, un schéma consensus à 8 loci a été proposé. Dans un second temps, une étude de la sensibilité de ce pathogène à l'amphotéricine B et au voriconazole a été menée par deux techniques d'évaluation des CMI : microdilution CLSI M38-A2 et bandelettes E-test. Devant le paradoxe entre une sensibilité diminuée in vitro au voriconazole et la recommandation de cette molécule pour le traitement curatif de la fusariose humaine, des mécanismes de résistance ont été exploré. L'hypothèse d'un phénomène d'efflux n'a pas été retenue alors que celle d'une modification de la cible, la 14 alpha stérol déméthylase, peut être envisagée après la description de différentes mutations pour les isoformes CYP51A, B et C
- 31 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Typage moléculaire du complexe d'espèces Fusarium solani et détermination de son mécanisme de résistance au voriconazole
Le complexe d'espèces Fusarium solani regroupe des champignons phytopathogènes également impliqués en pathologie humaine dans des infections parfois profondes et souvent de mauvais pronostic. Dans un premier temps, une méthode de MLST, s'appuyant sur 5 gènes de ménage a donc été développée. Validée sur 51 isolats épidémiologiquement distincts, cette méthode stable et reproductible présente un pouvoir discriminant de 99,1 %. Après comparaison à la technique de référence utilisée en phylogénie, un schéma consensus à 8 loci a été proposé. Dans un second temps, une étude de la sensibilité de ce pathogène à l'amphotéricine B et au voriconazole a été menée par deux techniques d'évaluation des CMI : microdilution CLSI M38-A2 et bandelettes E-test. Devant le paradoxe entre une sensibilité diminuée in vitro au voriconazole et la recommandation de cette molécule pour le traitement curatif de la fusariose humaine, des mécanismes de résistance ont été exploré. L'hypothèse d'un phénomène d'efflux n'a pas été retenue alors que celle d'une modification de la cible, la 14 alpha stérol déméthylase, peut être envisagée après la description de différentes mutations pour les isoformes CYP51A, B et C
- Open Access
- 11 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1)
Compassionate Use of Olorofim for Invasive Mold Infections: A Nationwide Observational Study in France
Background: The increasing incidence of resistant invasive mold infections (IMIs) has highlighted the need for novel antifungal agents. Olorofim, a first-in-class orotomide, has shown promising efficacy in a recent phase II study, but clinical data remain limited. Methods: We conducted a retrospective multicenter cohort study in France, including all patients who received olorofim under compassionate use for proven or probable non-Mucorales IMIs. Eligible patients had IMIs refractory to or intolerance to standard antifungals or no effective treatment options. Efficacy was defined as mycological and clinical control of infection; safety was also assessed. Results: Between January 2020 and December 2023, 17 patients (median age, 39 years) received olorofim. Underlying conditions included primary immunodeficiency (n = 4) and lung transplantation (n = 5). Sites of infection included the lung (88.2%) and the central nervous system (23.5%), with 5 cases of disseminated disease. In total, 23 strains were identified, mostly Aspergillus fumigatus (34.8%) and Microascus spp (13%). The median duration of prior antifungal therapy was 9.1 months. Olorofim was used primarily for refractory IMIs (70.6%) and in combination with other antifungals in 82.4% of cases. Olorofim minimum inhibitory concentrations were ≤0.5 mg/L in the 8 available isolates. Among 15 evaluable patients, 5 (33.3%) achieved clinical and mycological success, 7 (46.7%) had partial responses, and 3 (20%) experienced treatment failure. The 3-month mortality rate was 29.4% (5 of 17). No severe adverse events were reported. Conclusions: Olorofim exhibited potential efficacy and good tolerability in patients with refractory IMIs. Further data from ongoing clinical trials are needed to confirm these findings.
- 11 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1)
Open AccessCompassionate Use of Olorofim for Invasive Mold Infections: A Nationwide Observational Study in France
Background: The increasing incidence of resistant invasive mold infections (IMIs) has highlighted the need for novel antifungal agents. Olorofim, a first-in-class orotomide, has shown promising efficacy in a recent phase II study, but clinical data remain limited. Methods: We conducted a retrospective multicenter cohort study in France, including all patients who received olorofim under compassionate use for proven or probable non-Mucorales IMIs. Eligible patients had IMIs refractory to or intolerance to standard antifungals or no effective treatment options. Efficacy was defined as mycological and clinical control of infection; safety was also assessed. Results: Between January 2020 and December 2023, 17 patients (median age, 39 years) received olorofim. Underlying conditions included primary immunodeficiency (n = 4) and lung transplantation (n = 5). Sites of infection included the lung (88.2%) and the central nervous system (23.5%), with 5 cases of disseminated disease. In total, 23 strains were identified, mostly Aspergillus fumigatus (34.8%) and Microascus spp (13%). The median duration of prior antifungal therapy was 9.1 months. Olorofim was used primarily for refractory IMIs (70.6%) and in combination with other antifungals in 82.4% of cases. Olorofim minimum inhibitory concentrations were ≤0.5 mg/L in the 8 available isolates. Among 15 evaluable patients, 5 (33.3%) achieved clinical and mycological success, 7 (46.7%) had partial responses, and 3 (20%) experienced treatment failure. The 3-month mortality rate was 29.4% (5 of 17). No severe adverse events were reported. Conclusions: Olorofim exhibited potential efficacy and good tolerability in patients with refractory IMIs. Further data from ongoing clinical trials are needed to confirm these findings.
- Open Access
- 29 September 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (10)
When Emerging Fungal Infections Mimic Tuberculosis: First Reported Case of Invasive Emergomyces europaeus Infection in a Man With Immunocompromise Living in France
Emergomycosis is an emerging thermally dimorphic fungal infection primarily observed in individuals with HIV and is associated with cutaneous, pulmonary, or disseminated manifestations. We report the first case of invasive infection by Emergomyces europaeus involving both the lungs and bone marrow in a person with immunocompromise, identified through molecular tools.
- 29 September 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (10)
Open AccessWhen Emerging Fungal Infections Mimic Tuberculosis: First Reported Case of Invasive Emergomyces europaeus Infection in a Man With Immunocompromise Living in France
Emergomycosis is an emerging thermally dimorphic fungal infection primarily observed in individuals with HIV and is associated with cutaneous, pulmonary, or disseminated manifestations. We report the first case of invasive infection by Emergomyces europaeus involving both the lungs and bone marrow in a person with immunocompromise, identified through molecular tools.
- Open Access
- 6 September 2025
- Published by Elsevier in Journal of Microbiological Methods
- Vol. 237, 107250
In vivo Fusarium virulence and efficacy of voriconazole in a Galleria mellonella model of invasive fusariosis
- 6 September 2025
- Published by Elsevier in Journal of Microbiological Methods
- Vol. 237, 107250
Open AccessIn vivo Fusarium virulence and efficacy of voriconazole in a Galleria mellonella model of invasive fusariosis
- 2 April 2025
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 63 (4)
Clustered cases of Candida auris colonization: Roles of the infection prevention and control department and the mycology laboratory in controlling transmission
Candida auris is an emerging yeast that is responsible for outbreaks via nosocomial transmission. This study describes two cases of C. auris colonization, with confirmed interhospital transmission in the absence of travel history for the index case, although multiple risk factors were present. The role of the infection prevention and control department is essential in implementing barrier measures to limit yeast transmission, whereas the mycology laboratory plays a crucial role in the rapid and effective detection of potential contact cases, as well as environmental contamination.
- 2 April 2025
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 63 (4)
Clustered cases of Candida auris colonization: Roles of the infection prevention and control department and the mycology laboratory in controlling transmission
Candida auris is an emerging yeast that is responsible for outbreaks via nosocomial transmission. This study describes two cases of C. auris colonization, with confirmed interhospital transmission in the absence of travel history for the index case, although multiple risk factors were present. The role of the infection prevention and control department is essential in implementing barrier measures to limit yeast transmission, whereas the mycology laboratory plays a crucial role in the rapid and effective detection of potential contact cases, as well as environmental contamination.
- Open Access
- 24 January 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (2) , 91
Reevaluating the Value of (1,3)-β-D-Glucan for the Diagnosis of Intra-Abdominal Candidiasis in Critically Ill Patients: Current Evidence and Future Directions
Intra-abdominal candidiasis (IAC) is associated with significant diagnostic and therapeutic challenges in critically ill patients. Traditional fungal cultures are slow, delaying appropriate antifungal treatment. (1,3)-β-D-glucan (BDG), a component of the fungal cell wall, has emerged as a potential biomarker for IAC, but its use in ICU settings is complicated by frequent false-positives results from invasive procedures and underlying conditions. This review examines the diagnostic value of BDG when present in serum and peritoneal fluid. While serum BDG is effective for excluding invasive fungal infections like candidemia, its specificity for IAC remains low in critically ill patients. Recent studies suggest that BDG levels in peritoneal fluid may provide better diagnostic accuracy, distinguishing IAC from bacterial peritonitis with higher specificity. We discuss the advantages, limitations, and practical aspects of BDG testing, emphasizing the potential of peritoneal BDG as a complementary tool. Further research is needed to refine diagnostic thresholds, validate its clinical utility, and establish the role of peritoneal BDG in improving timely, targeted antifungal treatment for IAC.
- 24 January 2025
- Published by MDPI AG in Journal of Fungi
- Vol. 11 (2) , 91
Open AccessReevaluating the Value of (1,3)-β-D-Glucan for the Diagnosis of Intra-Abdominal Candidiasis in Critically Ill Patients: Current Evidence and Future Directions
Intra-abdominal candidiasis (IAC) is associated with significant diagnostic and therapeutic challenges in critically ill patients. Traditional fungal cultures are slow, delaying appropriate antifungal treatment. (1,3)-β-D-glucan (BDG), a component of the fungal cell wall, has emerged as a potential biomarker for IAC, but its use in ICU settings is complicated by frequent false-positives results from invasive procedures and underlying conditions. This review examines the diagnostic value of BDG when present in serum and peritoneal fluid. While serum BDG is effective for excluding invasive fungal infections like candidemia, its specificity for IAC remains low in critically ill patients. Recent studies suggest that BDG levels in peritoneal fluid may provide better diagnostic accuracy, distinguishing IAC from bacterial peritonitis with higher specificity. We discuss the advantages, limitations, and practical aspects of BDG testing, emphasizing the potential of peritoneal BDG as a complementary tool. Further research is needed to refine diagnostic thresholds, validate its clinical utility, and establish the role of peritoneal BDG in improving timely, targeted antifungal treatment for IAC.
- Open Access
- 1 September 2023
- Published by MDPI AG in Journal of Fungi
- Vol. 9 (9) , 900
Interactions between Bacteria and Aspergillus fumigatus in Airways: From the Mycobiome to Molecular Interactions
Interactions between different kingdoms of microorganisms in humans are common but not well described. A recent analysis of the mycobiome has described the presence of different fungi and their positive and/or negative interactions with bacteria and other fungi. In chronic respiratory diseases, these different microorganisms form mixed biofilms to live inside. The interactions between Gram-negative bacteria and filamentous fungi in these biofilms have attracted more attention recently. In this review, we analyse the microbiota of the respiratory tract of healthy individuals and patients with chronic respiratory disease. Additionally, we describe the regulatory mechanisms that rule the mixed biofilms of Aspergillus fumigatus and Gram-negative bacteria and the effects of this biofilm on clinical presentations.
- 1 September 2023
- Published by MDPI AG in Journal of Fungi
- Vol. 9 (9) , 900
Open AccessInteractions between Bacteria and Aspergillus fumigatus in Airways: From the Mycobiome to Molecular Interactions
Interactions between different kingdoms of microorganisms in humans are common but not well described. A recent analysis of the mycobiome has described the presence of different fungi and their positive and/or negative interactions with bacteria and other fungi. In chronic respiratory diseases, these different microorganisms form mixed biofilms to live inside. The interactions between Gram-negative bacteria and filamentous fungi in these biofilms have attracted more attention recently. In this review, we analyse the microbiota of the respiratory tract of healthy individuals and patients with chronic respiratory disease. Additionally, we describe the regulatory mechanisms that rule the mixed biofilms of Aspergillus fumigatus and Gram-negative bacteria and the effects of this biofilm on clinical presentations.
- Open Access
- 16 November 2022
- Published by MDPI AG in Microorganisms
- Vol. 10 (11) , 2270
Simulated Microgravity Created Using a Random Positioning Machine Induces Changes in the Physiology of the Fusarium solani Species Complex
Fusarium is a phytopathogenic fungus involved in human pathology and is present in space stations. It is essential to understand the effects of microgravity on the physiology of this fungus to determine the potential risks to the health of crew members and to propose the necessary countermeasures. This study aimed to determine changes in the physiological parameters of the Fusarium solani species complex under simulated microgravity generated using a random positioning machine (RPM) and phenotypic approaches. We observed increased growth, spore production, and germination while biofilm production was reduced under RPM exposure. These in vitro data show the importance of further studying this fungus as it has been repeatedly demonstrated that microgravity weakens the immune system of astronauts.
- 16 November 2022
- Published by MDPI AG in Microorganisms
- Vol. 10 (11) , 2270
Open AccessSimulated Microgravity Created Using a Random Positioning Machine Induces Changes in the Physiology of the Fusarium solani Species Complex
Fusarium is a phytopathogenic fungus involved in human pathology and is present in space stations. It is essential to understand the effects of microgravity on the physiology of this fungus to determine the potential risks to the health of crew members and to propose the necessary countermeasures. This study aimed to determine changes in the physiological parameters of the Fusarium solani species complex under simulated microgravity generated using a random positioning machine (RPM) and phenotypic approaches. We observed increased growth, spore production, and germination while biofilm production was reduced under RPM exposure. These in vitro data show the importance of further studying this fungus as it has been repeatedly demonstrated that microgravity weakens the immune system of astronauts.
- Open Access
- 20 May 2022
- Published by MDPI AG in Journal of Fungi
- Vol. 8 (5) , 533
CYP51 Mutations in the Fusarium solani Species Complex: First Clue to Understand the Low Susceptibility to Azoles of the Genus Fusarium
Members of Fusarium solani species complex (FSSC) are cosmopolitan filamentous fungi responsible for invasive fungal infections in immunocompromised patients. Despite the treatment recommendations, many strains show reduced sensitivity to voriconazole. The objective of this work was to investigate the potential relationship between azole susceptibility and mutations in CYP51 protein sequences. Minimal inhibitory concentrations (MICs) for azole antifungals have been determined using the CLSI (Clinical and Laboratory Standards Institute) microdilution method on a panel of clinical and environmental strains. CYP51A, CYP51B and CYP51C genes for each strain have been sequenced using the Sanger method. Amino acid substitutions described in multiple azole-resistant Aspergillus fumigatus (mtrAf) strains have been sought and compared with other Fusarium complexes’ strains. Our results show that FSSC exhibit point mutations similar to those described in mtrAf. Protein sequence alignments of CYP51A, CYP51B and CYP51C have highlighted different profiles based on sequence similarity. A link between voriconazole MICs and protein sequences was observed, suggesting that these mutations could be an explanation for the intrinsic azole resistance in the genus Fusarium. Thus, this innovative approach provided clues to understand low azole susceptibility in FSSC and may contribute to improving the treatment of FSSC infection.
- 20 May 2022
- Published by MDPI AG in Journal of Fungi
- Vol. 8 (5) , 533
Open AccessCYP51 Mutations in the Fusarium solani Species Complex: First Clue to Understand the Low Susceptibility to Azoles of the Genus Fusarium
Members of Fusarium solani species complex (FSSC) are cosmopolitan filamentous fungi responsible for invasive fungal infections in immunocompromised patients. Despite the treatment recommendations, many strains show reduced sensitivity to voriconazole. The objective of this work was to investigate the potential relationship between azole susceptibility and mutations in CYP51 protein sequences. Minimal inhibitory concentrations (MICs) for azole antifungals have been determined using the CLSI (Clinical and Laboratory Standards Institute) microdilution method on a panel of clinical and environmental strains. CYP51A, CYP51B and CYP51C genes for each strain have been sequenced using the Sanger method. Amino acid substitutions described in multiple azole-resistant Aspergillus fumigatus (mtrAf) strains have been sought and compared with other Fusarium complexes’ strains. Our results show that FSSC exhibit point mutations similar to those described in mtrAf. Protein sequence alignments of CYP51A, CYP51B and CYP51C have highlighted different profiles based on sequence similarity. A link between voriconazole MICs and protein sequences was observed, suggesting that these mutations could be an explanation for the intrinsic azole resistance in the genus Fusarium. Thus, this innovative approach provided clues to understand low azole susceptibility in FSSC and may contribute to improving the treatment of FSSC infection.
- Open Access
- 1 April 2009
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 47 (4) , 1269-1273
Molecular Diagnosis of Disseminated Adiaspiromycosis Due toEmmonsia crescens
Emmonsia crescensis a saprophytic fungus that is distributed worldwide, causing diseases mostly in rodents. It has also been described, though rarely, as an etiologic agent of pulmonary pathology in humans, potentially leading to death. A case of pulmonary adiaspiromycosis is reported in a 30-year-old immunocompetent man. The patient presented with a history of several weeks of weakness, cough, fever, and weight loss of 10 kg. Clinical and radiographic findings showed pulmonary lesions consistent with tuberculosis or histoplasmosis, but no pathogen was found with classical microbiological procedures. The diagnosis of adiaspiromycosis due toEmmonsia crescenswas initially made using molecular biology techniques. Histological observations subsequently confirmed the presence of adiaspores in granulomas. To our knowledge, this is the first case of adiaspiromycosis diagnosed by PCR and sequencing. The patient was treated with itraconazole and was seen at 1 month with symptomatic improvement. Here we will discuss this rare fungal infection and its difficult treatment and diagnosis. As represented in this case, molecular biology is a powerful method to optimize diagnostic tests and therefore improve the care of the infected patient.
- 1 April 2009
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 47 (4) , 1269-1273
Open AccessMolecular Diagnosis of Disseminated Adiaspiromycosis Due toEmmonsia crescens
Emmonsia crescensis a saprophytic fungus that is distributed worldwide, causing diseases mostly in rodents. It has also been described, though rarely, as an etiologic agent of pulmonary pathology in humans, potentially leading to death. A case of pulmonary adiaspiromycosis is reported in a 30-year-old immunocompetent man. The patient presented with a history of several weeks of weakness, cough, fever, and weight loss of 10 kg. Clinical and radiographic findings showed pulmonary lesions consistent with tuberculosis or histoplasmosis, but no pathogen was found with classical microbiological procedures. The diagnosis of adiaspiromycosis due toEmmonsia crescenswas initially made using molecular biology techniques. Histological observations subsequently confirmed the presence of adiaspores in granulomas. To our knowledge, this is the first case of adiaspiromycosis diagnosed by PCR and sequencing. The patient was treated with itraconazole and was seen at 1 month with symptomatic improvement. Here we will discuss this rare fungal infection and its difficult treatment and diagnosis. As represented in this case, molecular biology is a powerful method to optimize diagnostic tests and therefore improve the care of the infected patient.